Pharma Contract Sales Market To Be Worth $7.36bn In 2020, New Visiongain Analysis Predicts

10 September 2018
Pharma

A new report by visiongain forecasts that the global pharma contract sales market will generate $7.36 billion in 2020. That revenue prediction and others appear in Pharma Contract Sales Market 2016-2026: Revenue Forecasts for Outsourced Detailing, Including Teledetailing and eDetailing, as well as Medical Education and Sample Management Services. That study gains publication in March 2016. Visiongain is a business information publisher and consultancy in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“The pharmaceutical contract sales market consists of revenues achieved by CSOs (contract sales organisations), which assist other companies in the sales and marketing of products and services. Outsourcing medical sales offers many benefits to pharmaceutical companies, and contract sales is one of the fastest growing sectors of the overall pharmaceutical outsourcing market, driven by a range of factors including new technologies, sales models and drug launches. However, the market faces many challenges, including the declining access to doctors, patent expiries for leading products, and large companies choosing to retain sales activities in-house.”

Visiongain’s updated analysis provides multilevel revenue forecasts for the pharma contract sales market from 2016 to 2026.

First it shows revenue predictions to 2026 for seven submarkets:

• Contract detailing (personal promotion/field sales)
• Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and other selling operations
• Medical education services
• Sample management services.

In addition, there appear four revenue forecasts to 2026 for prominent therapeutic segments of the overall pharma contract sales market:

• Cardiovascular diseases
• Metabolic disorders
• Cancer treatments
• Other drugs (grouped prediction).

That investigation also shows revenue forecasts to 2026 for 11 national markets:

• USA
• Japan
• Germany, UK, France, Italy and Spain
• China, India, Brazil and Russia.

Companies that new study assesses include Quintiles, inVentiv Health, UDG Healthcare and Publicis Touchpoint Solutions. Interviews with three organisations – OnCall, Apodi and Hilver – also appear.

Visiongain’s new report discusses forces stimulating revenue expansion over the next ten years, as well as forces restraining the CSO industry. Pharma Contract Sales Market 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices. Their purpose is to help organisations assess the potentials of industries and markets.

Recent News

Visiongain publishes Constipation Nutraceuticals Market Report 2020-2030

Nutraceuticals are the products that provide medicinal and health benefits to the people. These products provide additional nutritional value to the foodstuff.

01 June 2020

Read

“Precision Medicine Market is Poised to Surpass US$67 billion in 2020” says new Visiongain report

Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.

27 May 2020

Read

Visiongain publishes Colon Targeting Drug Delivery Market Report 2020-2030

The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.

27 May 2020

Read

“The global automation in biopharma market is estimated to reach USD 1.23 billion by 2025” says new Visiongain report

The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.

22 May 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever